#USA #New York #Telehealth #Biotia #UTI Treatment

Biotia's Groundbreaking 'Test to Treat' Option for Recurrent UTIs

In an exciting development for patient care, Biotia has officially launched a new "test to treat" offering specifically designed for individuals suffering from recurrent urinary tract infections (UTIs). This innovative solution aims to simplify the diagnostic and treatment process, enabling patients to conduct tests from the comfort of their homes while also ensuring they receive expert care from professionals trained in managing these challenging conditions.

Understanding the UTI Challenge

Each year, approximately 11 million cases of UTIs are reported in the United States. Traditionally, diagnosing these infections often involves urine cultures, which can be both time-consuming and prone to inaccuracies. Alarmingly, traditional urine cultures fail about 30% of the time, especially when it comes to detecting infections caused by anaerobes, fungi, and other hard-to-identify pathogens. As a result, many individuals struggle to get the accurate diagnosis and appropriate treatment they need, which is particularly frustrating for those with recurrent UTIs.

What Is the 'Test to Treat' Offering?

The newly announced 'test to treat' pathway allows patients to conveniently collect a urine sample for advanced laboratory testing without leaving home. Through this method, Biotia enables the use of its advanced BIOTIA-ID Urine Test, which leverages next-generation sequencing and artificial intelligence to identify over 40 significant uropathogens. This cutting-edge technology not only improves accuracy but also provides insights into antimicrobial resistance, ensuring that patients receive tailored treatment based on their specific diagnosis.

After obtaining their test results, patients can seamlessly transition to virtual consultations with clinicians from Biotia’s telehealth partner, Clinova.Solutions. This streamlined process represents a major step forward in addressing the gaps in UTI diagnostics and management, ultimately allowing patients to receive swift and effective care.

The Importance of Access to Advanced Diagnostics

Dr. Nagy-Szakal, Biotia's Chief Medical Officer, emphasizes the importance of providing patients with effective solutions to combat recurring UTIs. He notes, “Patients with recurrent or chronic UTIs face significant challenges in obtaining an accurate diagnosis and effective treatment. Instead of enduring repeated doctor visits and lab tests, we provide a streamlined solution—one comprehensive test paired with telehealth consultation to help patients quickly address their symptoms.” This comprehensive approach aims to mitigate the frustration and discomfort associated with recurrent UTIs, fostering a better patient experience.

Availability and Eligibility

Biotia's BIOTIA-ID Urine Test is currently available across all 50 states in the U.S. Eligible patients can easily check their qualifications and get started on this novel test and treatment pathway by visiting Biotia’s official website at www.biotia.io.

Biotia has established itself as a pioneering precision diagnostics company, focusing on merging clinical metagenomics with artificial intelligence to drive advancements in the field of infectious disease diagnostics. Their commitment to improving health outcomes globally is evident in the careful consideration they've given to the challenges faced by patients.

For anyone struggling with recurrent UTIs, Biotia’s innovative approach may signify a new era in patient care, offering hope for a more effective and hassle-free experience in managing their health. For more details and to stay connected, visit Biotia’s social media on Instagram, Facebook, and LinkedIn, or check out their official website at www.biotia.io.